Harmony Biosciences Reveals Encouraging Data from Phase 2 Pitolisant Study in PWS Patients

Harmony Biosciences has presented new secondary endpoint data concerning the use of pitolisant, an investigational drug, for the treatment of excessive daytime sleepiness (EDS) in Prader-Willi syndrome.

According to a recent press release Harmony Biosciences released, the Phase 2 signal-detection study showed improvements in behavioral disturbances, especially in the higher-dose pitolisant group, as well as reductions in caregiver ratings of EDS severity and some improvements in hyperphagia. The Phase 3 registrational TEMPO study, expected to begin in Q4 2023, will further assess pitolisant's safety and efficacy in PWS patients. 

Learn more about these findings at the button below.

Share this!

Scroll to top